1Ramsay RE,Rowan AJ,Pryor FM,et al.Special considerations in treating the elderly patient with epilepsy[J].Neurology,2004;62(Suppl 2):S24-9. 被引量：1
2Pryor FM,Ramsay RE,Rowan AJ,et al.Epilepsy in older adults:update from VA Cooperative Study #428[J].Epilepsia,2002;43(suppl 7):165-6. 被引量：1
3LaRoche SM,Helmers SL.Epilepsy in the elderly[J].Neurologist,2003;9(5):241-9. 被引量：1
4Mohamed K,Appleton R,Rosenbloom L.Efficacy and tolerability of topiramate in childhood and adolescent epilepsy:a clinical experience[J].Seizure,2000;9(2):137-41. 被引量：1
5Mehta S,Pryor FM,Kraut L,et al.Efficacy and tolerability of topiramate in the elderly population[J].Epilepsia,2002;43(Suppl 7):165-74. 被引量：1
6Stephen LJ.Drug treatment of epilepsy in elderly people[J].Drugs Aging,2003;20(2):141-52. 被引量：1
7Ritter F,Glauser TA,Elterman RD,et al.Effectiveness,tolerability,and safety of topiramate in children with partial-onset seizures.Topiramate YP Study Group[J].Epilepsia,2000;41(Suppl 1):82-5. 被引量：1
8Wong IC,Lhatoo SD.Adverse reactions to new anticonvulsant drugs[J].Drug Saf,2000;23(1):35-56. 被引量：1
9Reife R,Pledger G,Wu SC.Topiramate as add-on therapy:pooled analysis of randomized controlled trials in adults[J].Epilepsia,2000;41(suppl 1):66-71. 被引量：1
10Shorvon SD.Safety of topiramate:adverse events and relationships to dosing[J].Epilepsia,1996;37(Suppl 2):18-22. 被引量：1
